Professor Rosalind Eeles is a distinguished Professor of Oncogenetics at The Institute of Cancer Research, University of London, UK. She completed her medical training at The University of Cambridge and St Thomas' Hospital, London. Professor Eeles is a Fellow of the Royal College of Physicians and the Royal College of Radiologists (Clinical Oncology Faculty), London. She holds accreditation in Clinical Oncology and possesses extensive sub-specialist experience in Cancer Genetics.

Professor Eeles' oncological practice focuses on radiotherapy and chemotherapy for Uro-Oncology. In her cancer genetics practice, she specialises in cancer risk assessment, screening advice, and the management of increased cancer risk in adults for various cancer sites. She is a leading expert in how new cancer genetics influence treatment decisions. Her contributions to the field include editing a specialist textbook on Cancer Prevention and Screening, which won the BMA Chairman's award in 2019. She has authored over 500 original research papers and holds an international reputation in Cancer Genetic Clinical Management and research.

Her expertise is particularly notable in the management of individuals with mutations in the breast, ovarian, and prostate cancer predisposition genes, including BRCA1, BRCA2, and other related genes. Professor Eeles has served on several genetics advisory committees and edited a special edition of Familial Cancer, focusing on new models of cancer genetics service delivery.

Professor Eeles is an active member of several learned societies, including ESTRO, ESMO, ASHG, AACR, BAUS, ESHG, ASCO, BSGM, and CGG UK. Her outside interests include opera and art.

Conditions Treated
- Genetic predisposition to various cancers, including breast, ovarian, and prostate cancer

Procedures and Treatments
- Cancer risk assessment
- Screening advice
- Management of increased cancer risk
- Radiotherapy
- Chemotherapy

Professor Rosalind Eeles has been a pivotal figure in the field of oncogenetics since her appointment, contributing significantly to both clinical practice and research. Her work continues to shape the future of cancer genetics and its application in personalised medicine.